Although cytotoxic chemotherapy is widely used for treatment of many forms of cancer, failure to respond to anticancer drugs and resistance to treatment are major obstacles to satisfactory clinical outcome. Over 30% of acute myeloid leukemia (AML) 8 patients fail to respond to the nucleoside analog cytarabine (Ara-C [cytosine arabinoside]), the main drug used for AML treatment, and a substantial proportion fail to achieve long-term remission, whereas others respond to reduced levels of the drug (1 ) . Currently, patients undergo no prescreening for any of the courses of cytotoxic therapy to determine potential response (1 ) . For nonresponding patients, this lack of screening can result in a delay in commencement of effective treatment and unnecessary exposure to cytotoxic drugs with associated morbidity and mortality due to side effects and potential drug-induced secondary malignancies (2 ) . There is a need for rapid screening of patient samples to determine level of drug response before commencement of treatment that not only will give increased patient benefits, but also reduce healthcare costs (1 ) . It is anticipated that such a test could be analogous to the existing antibiotic sensitivity tests routinely used in clinical settings before antibiotic treatment for infection.
The nucleoside analog Ara-C is one of the most active single anticancer agents and is the main drug of chemotherapy for AML (3, 4 ) . In vivo, Ara-C is trans-ported into the cell via the human equilibrium nucleoside transporter (hENT1) and is rapidly phosphorylated by deoxycytidine kinase (dCK) to its monophosphate form, cytosine arabinoside monophosphate (Ara-CMP), which is further phosphorylated by nucleoside kinases and finally to the triphosphorylated and active form, cytosine arabinoside triphosphate (Ara-CTP). Drug inactivation can result from Ara-CMP conversion into Ara-uracil by cytidine deaminase (cdd), or from dephosphorylation of Ara-CMP by cytoplasmic nucleotidase (3 ) . The antiproliferative and cytotoxic effects of Ara-CTP are largely due to its ability to interfere with DNA polymerase and its incorporation into DNA strands leading to chain termination and DNA synthesis arrest (4 ) .
Chemoresistance to Ara-C can arise from a number of factors influencing the rate of Ara-CTP formation and incorporation into DNA (5 ), including low drug uptake, conversion into Ara-uracil by cytidine deaminase, or dephosphorylation of active metabolite by cytoplasmic nucleotidase (6 ) . Intracellular concentrations of Ara-CTP are reported to correlate with response to Ara-C therapy (4 ) . In vitro assessment of Ara-C efficacy has previously involved measurement of cell death, assessed by colony forming units-blast clonogenic assays (7 ) . This methodology involves primary cell culture over Ն3 days (7 ) and is not suitable for routine screening. In clinical practice, patients are treated with regimens including Ara-C regardless of their possible nonresponse to the drug and, as a result, suffer from debilitating side effects (2, 8 ) . Patients are given induction therapy over a period of weeks, before sensitivity or resistance is determined by leukemic cell count (4 ).
Recombinant cell-based bioluminescence technology is an approach that has received increasing attention for biomedical applications (9 ) and has previously been used for determination of androgen bioactivity in clinical samples (10 ) . This technology has the potential to detect anticancer drug activity in malignant cells from clinical samples, within a period of hours. Light emission from bioluminescent bacteria is due to the activity of bacterial luciferase, which catalyzes the oxidation of reduced flavin mononucleotide (FMNH 2 ) and a long-chain aliphatic aldehyde in the presence of O 2 to produce FMN and acid with the emission of blue-green light. The genes coding for the luciferase [alkanal monooxygenase subunit alpha (luxA) 9 and alkanal monooxygenase subunit beta (13, 14 ) . Ara-C has no effect on Escherichia coli, since the bacteria lack dCK that phosphorylates Ara-C into its active form and they actively deaminate Ara-C into Ara-uracil through the activity of cytidine/deoxycytidine deaminase (cdd). Wang et al. (15 ) constructed a cdd-deficient E. coli strain (SØ5218) that, upon the expression of the human deoxycytidine kinase (DCK) gene, exhibited reduced relative growth in the presence of Ara-C in minimal growth medium. Therefore, this indicates that expression of human dCK in SØ5218 leads to the incorporation of Ara-CTP into bacterial DNA. However, the growth inhibitory effect of Ara-C was completely abolished when assayed in rich growth medium due to incorporation of cytosine triphosphate instead of the toxic analog Ara-CTP into bacterial DNA (15 ) .
The main aim of this study was the construction of a pyrimidine-requiring, cdd-deficient mutant of E. coli MG1655 strain with enhanced sensitivity toward Ara-C in rich medium and its use as a bioluminescent biosensor in an 8-h assay to determine Ara-C uptake as well as its phosphorylation by human leukemic cells. The assay provides information on the phenotype of leukemic cells in clinical samples of peripheral blood or bone marrow.
Materials and Methods

BACTERIAL STRAINS, PLASMIDS, AND GROWTH MEDIA
E. coli SØ5218 (a gift from S. Eriksson, University of Copenhagen) is a cdd-deficient strain expressing the human DCK cDNA on the isopropyl ␤-D-1-thiogalactopyranoside (IPTG)-inducible pTrc99-A plasmid (14 ) . E. coli MG1655 (a gift from K.J. Jensen, University of Copenhagen, Denmark) is a derivative of the wild-type E. coli K-12 that requires pyrimidine in minimal growth medium, due to suboptimal expression of the enzyme orotate phospho-ribosyltransferase coded for by the orotate phosphoribosyltransferase (pyrE) gene (16 ) . Both strains were made selfbioluminescent by transformation, using standard methods previously described (9 ) , with the broad-host vector pBBR1MCS-2 (17 ) carrying the luxCDABE cassette from Photorhabdus luminescens as an EcoRI PCR fragment. All chemicals and growth media were supplied by Sigma-Aldrich (www.sigmaaldrich. com) unless otherwise stated. Luria-Bertani growth medium was used for routine culturing of bacteria. The antibiotics tetracycline, ampicillin, and kanamycin were added at a final concentration of 10, 100, and 10 mg/L, respectively. Growth inhibition experiments were performed in Luria-Bertani growth medium, RPMI 1640 (Invitrogen, www.invitrogen.com), or AB minimal medium (16 ) plus 2.0 g/L glucose and 2.0 g/L vitaminfree casamino acids and supplemented with thiamine and leucine at final concentrations of 1 and 20 mg/L, respectively.
CELL LINES, BONE MARROW, AND BLOOD SAMPLES
The monocytic AML cell lines KG-1a and THP-1 (DSMZ, www.dsmz.de) were grown and maintained as a cell suspension in RPMI 1640 medium supplemented with 2 mmol/L glutamine (Invitrogen) and 10% fetal calf serum (Biosera, www.biosera.com) at 37°C and 5% CO 2 . Cultures were maintained at a density of 1-4 ϫ 10 6 cells/mL and were monitored by vital staining using trypan blue. Cryopreserved bone marrow samples, previously separated by density gradient centrifugation to yield the mononuclear cell fraction, were thawed and resuspended in RPMI 1640 medium before incubation with Ara-C. Mononuclear cells from fresh AML peripheral blood samples (collected from patients at Frimley Park Hospital, Surrey, UK, and Bristol Haematology and Oncology Centre, Bristol, UK, after obtaining informed consent) were also isolated by density gradient centrifugation and resuspended in RPMI 1640 medium. In all cases, samples were obtained from patients at diagnosis, before the start of treatment, and with blood blast burdens Ͼ80% and were analyzed blind to avoid bias. Subsequent clinical outcome after induction chemotherapy with Ara-C-containing treatment cycles was available in all cases. Ara-C was added at a final concentration of 25 mol/L, which represents the equivalent of the standard in vivo dose of 200 mg ⅐ m Ϫ2 ⅐ day Ϫ1 (based on an 80-kg individual (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol56/issue12) (18 ) .
CONSTRUCTION OF A cdd-DEFICIENT MUTANT OF E. coli MG1655
A library of E. coli MG1655 mutants was constructed by using random transposition mutagenesis with P1 phage carrying Tn10 transposon, which can transpose from the phage into the E. coli chromosome, according to Miller (19 ) with slight modification. Briefly, E. coli MG1655 mutants were grown in Luria-Bertani broth until the midexponential phase and were infected with P1 phage at a multiplicity of infection of approximately 5. The infected cells were plated on Luria-Bertani agar plates containing tetracycline to select for mutants carrying the transposon. The cdd mutants were selected by growth after 24-h incubation at 37°C on plates containing 10 mg/L of the analog 5-fluoro-2Јdeoxycytidine, which is toxic to E. coli-containing cdd activity. The phenotype of the cdd mutant (E. coli HA1) was confirmed by the absence of cytidine deaminase activity.
WESTERN BLOT ANALYSIS FOR DCK EXPRESSION
Lyophilized HA1 cells were reconstituted with 1 mL water per vial and incubated at 37°C for 1 h. Cells were diluted 1/10 in prewarmed RPMI 1640 containing tetracycline, ampicillin, and kanamycin, added at a final concentration of 10, 100, and 10 mg/L, respectively. A 1-mL t ϭ 0 sample was removed, and 1 mmol/L IPTG was added to the remaining culture. Cells were incubated at 37°C with shaking at 220 rpm. Samples of 1 mL were removed every 30 min for 3 h. The samples collected at different time points were centrifuged, and the supernatant was removed. Pellets were lysed with 100 L CelLyticB containing 2 mmol/L phenylmethanesulfonyl fluoride and 10 mg/L DNase I, to extract soluble protein. Protein concentrations were determined by Bradford Assay (A595 nm) using BSA as a standard, and 100 ng protein for each sample was then separated on a 12% SDS-PAGE gel for 1 h at 300 V. The separated proteins were transferred to a nitrocellulose membrane for 1 h at 100 V. Membranes were blocked for 1 h at room temperature with 3% BSA in Trisbuffered saline with Tween. Detection of protein was carried out by using the anti-dCK primary antibody (rabbit polyclonal to dCK; Abcam AB38012, Abcam, www.abcam.com) at 1:500 dilution and goat antirabbit horse radish peroxidase-conjugated polyclonal as secondary conjugate (Sigma A0545) at 1:5000 dilution. Presence of bound horse radish peroxidase conjugate was detected by using the BM chemiluminescent detection system (Roche, www.roche.com) and standard x-ray film (Kodak, www.kodak.co.uk).
BIOSENSOR DOSE RESPONSE ANALYSIS
An overnight culture of E. coli HA1 was diluted to an absorbance (A) at 600 nm (600 A) of 0.1 in RPMI 1640 medium and incubated for 30 min at 37°C with shaking at 220 rpm. Samples of 200 L with either Ara-C or fludarabine (F-ara-A) concentrations of 0 -100 mol/L and 1 mmol/L IPTG were loaded into a black-walled microtiter plate (Invitrogen). Bioluminescence and growth (600 A) were monitored every 15 min for 15 h in a multimode microplate reader (Tecan, www. tecan.com).
CELL LYSIS ASSAY
Cell lines were harvested by centrifuging at 300g for 5 min at room temperature and resuspended in The effect of Ara-C concentrations (0.1, 1, 25, and 100 mol/L) on luminescence (A) and growth (B) of E. coli HA1 in the presence of IPTG; the effect of IPTG induction of dCK in the presence of Ara-C (C) is also shown. Growth was monitored by measuring 600 A; luminescence is shown as relative light units (RLU); n ϭ 10 and error bars represent SD. Table 3 in the online Data Supplement; ***P Ͻ 0.001). NS, not significant. RPMI 1640 with no additives at a concentration of 2 ϫ 10 6 cells/mL. Cell lines, peripheral blood, and bone marrow blasts were treated with 25 mol/L Ara-C for 30 min at 37°C and 5% CO 2 . After exposure to Ara-C, cultures were centrifuged as previously described and the supernatant was removed. Harvested cells were washed and resuspended in fresh RPMI 1640 medium. EDTA and saponin were added to cell suspensions at final concentrations of 1.5 mmol/L and 1.0 g/L, respectively. Samples were vortex-mixed for 30 s, and cell debris was removed by centrifugation at 2800g for 5 min at room temperature. Lysate samples were each mixed with an overnight culture of the reporter bacteria, freshly diluted to a 600 A of 0.1 in a black microtiter plate (Invitrogen).
A total of 1 mmol/L IPTG and 10 U alkaline phosphatase (AP) was added to the relevant samples. Bioluminescence and growth (600 A) were monitored in a Tecan multimode microplate reader. Ara-C toxicity was also assayed with a 3-day cytotoxicity assay using the Cell TiterGlo® Luminescent Cell Viability Assay kit (Promega, www.promega. com). Cells were treated as above with 25 mol/L Ara-C for 72 h at 37°C and 5% CO 2 , to allow cells to enter the S phase and hence be sensitized to Ara-CTP, before measuring intracellular levels of ATP according to the manufacturer's instructions (Promega G7570 Cell Titer-Glo Luminescent Cell Viability Assay).
STATISTICAL ANALYSIS
Statistical significance was determined by using oneway ANOVA with Bonferroni corrected post hoc tests (GraphPad Prism 4). Number of repeat treatments was 3 or more throughout; standard deviation was calculated for n ϭ 10 repeats, and mean and range is shown for n ϭ 3 repeats.
Results
E. coli SØ5218, the cdd-deficient strain constructed by Wang et al. (15 ) , expressing the human dCK gene, ex- hibited reduced relative growth in the presence of Ara-C in minimal medium but not in a rich growth medium, due to incorporation of cytosine triphosphate instead of the toxic analog Ara-CTP into bacterial DNA.
To measure Ara-C response in a nutrient-rich intracellular environment, an alternative cdd-deficient mutant of a bioluminescent E. coli MG1655 strain, requiring exogenous pyrimidine due to suboptimal expression of the enzyme orotate phosphoribosyltransferase coded for by the pyrE gene (16 ), was constructed by using transposon mutagenesis. This mutant was further transformed with pTrcHUMdCK (15 ) to give IPTG-inducible expression of dCK. The newly constructed bacterial biosensor, E. coli HA1, showed reduced growth in the presence of Ara-C, even when assayed in nutrient-rich medium (Fig. 1B) . Ara-C caused significantly (P Ͻ 0.001; see Table 2 in the online Data Supplement) increased light output from the biosensor (Fig. 1A ) with concentrations as low as 0.1 mol/L. This significantly increased light output was only observed during treatment with the pyrimidine analog Ara-C and only in the presence of IPTG-activated dCK (Fig. 1C) . The specificity of the biosensor to Ara-C was indicated by a lack of biosensor response in a control assay with the purine analog fludarabine ( Fig. 1 in the online Data Supplement shows that IPTG activation of dCK had no effect on E. coli HA1 treated with fludarabine).
To increase the specificity of the assay, direct effects of the active intracellular drug derivative, Ara-CTP, on the bacterial biosensor were monitored (Fig.  2) . The results indicate that Ara-CTP does not enter the reporter bacteria, showing no increase in light output compared with the untreated control, unless AP is added at the start of the assay. The increase in peak light output in the AP-treated samples (Fig. 2, A and B) is similar to that observed with Ara-C (Fig. 1A) and supports our reasoning. By measuring peak bioluminescence increase in the presence and absence of AP (ϩ/Ϫ), it is possible to quantify the intracellular conversion of Ara-C to Ara-CTP, within leukemic cells. Fig. 2 , A and C, show that there is good correlation between light output ϩ/Ϫ AP and nanomolar concentrations of Ara-CTP and also that concentrations as low as 25 nmol/L can be detected by a significant increase in light output (P Ͻ 0.05; see Table 3 in the online Data Supplement).
A Western blot for IPTG-induced expression of dCK in the biosensor showed a high level of expression after 3 h (Fig. 3A) , leading to the increase in bioluminescence (Fig. 3B) only in Ara-C-treated cells plus IPTG.
AML cell lines and leukemic cell samples from AML patients with known clinical outcome to Ara-C treatment were used to evaluate the assay outlined by the schematic in Fig. 4 . A 3-day cytotoxicity test confirmed that KG-1a cells were sensitive to Ara-C, whereas the THP-1 cell line was partially resistant (Fig.  5F ). Running the assay with and without AP in parallel enabled the determination of the relative proportion of Ara-C that had been converted within AML cells into Ara-CTP. THP-1 cells that had not converted Ara-C to Ara-CTP generated similar output whether or not AP was present in the assay (Fig. 5, C and D) . KG1-a cells generated the greatest difference (P Ͻ 0.001) in light output, in the presence of AP, due to conversion of Ara-C to Ara-CTP, indicating high drug response (Fig. 5, A and B) . The diagnostic discriminator, assuming that generation of Ara-CTP in AML cells is the major cause of cell death (4, 5 ) , is the maximal difference in light output between the IPTG (LI) and IPTG ϩ AP (LIP) curves that are shown in Fig. 5E .
Data were analyzed by single point measurement at peak light output, comparing treated and untreated samples ϩ/Ϫ AP, as shown in Fig. 5E . The calculation of the percentage response uses a simple formula:
Biosensor assay response (%)
Preliminary assay of stored blood and bone marrow samples taken at presentation from 12 known responding and 12 known nonresponding Ara-C-treated pa- tients gave biosensor assay responses between 21 and 128% (median 55%) for responding patients and between Ϫ7 and 6% (median 0%) for nonresponding patients (see Table 4 in the online Supplemental Data). A typical example of each type is shown in Fig. 6 ; patient sample CR (with clinical outcome of complete remission) showed a significant difference in the peak light output (P Ͻ 0.001) in the presence and absence of AP, indicating response to a drug (Fig. 6A) , whereas sample NR (nonresponsive clinical outcome) exhibited no significant difference (P Ͼ 0.05) in light output between the (ϩ/Ϫ) curves, indicating a low concentration of Ara-CTP in the cells (Fig. 6B) . The 3-day cytotoxicity test also showed that cells from patient sample CR were significantly more sensitive to Ara-C compared with cells from patient sample NR (Fig. 6C ).
Discussion
The cell lysis assay, using the bioluminescent bacterial biosensor as a reporter of Ara-C activity, relies on the response of bacteria to Ara-C. Because of the increased metabolic rate and shorter cell cycle time of bacteria, results can be achieved within a period of hours. In contrast, mammalian cells undergo slower cell division, which is the reason for the incubation times of 3 days or more needed to measure Ara-C cytotoxicity. The increase in light output from the biosensor, which closely correlates with the concentration of an active drug under assay conditions in clinical samples, gives a measure of mononuclear cell phenotype with regard to intracellular Ara-CTP production during the time interval that the cells are exposed to Ara-C.
The bioluminescence increase brought about by Ara-C in the biosensor is similar to previous reports of enhanced light emission in luciferase-based biosensors brought about by impairment of the bacterial intracellular equilibrium, leading to NADPH accumulation (20 ) , or by DNA damage (21 ) . It is reported that bioluminescence stimulates DNA repair in bacteria, possibly by providing photons for bacterial photolyase activity (22 ) and that lux genes are regulated by the bacterial SOS stress response (23 ) , which may explain the increase in bioluminescence in the presence of Ara-C.
The biosensor assay demonstrates Ara-C uptake and activity in mononuclear cells isolated from AML patient bone marrow and peripheral blood samples within 8 h. The assay is the first of its kind, showing phenotypic drug response within 8 h and here has been used in a retrospective study of 24 clinical samples. This is a preliminary validation study, and further work will include prospective, controlled randomized trials to establish the usefulness of the assay for AML and acute lymphoblastic leukemia, which account for 2% of cancers in the UK (24 ) . The assay has the potential to detect response to Ara-C of myeloid blasts, irrespective of whether they are obtained at diagnosis or at relapse/ nonresponse. This will be fully evaluated in prospective clinical trials. The assay demonstrates that Ara-C sensitivity of AML cells can be simply and accurately determined within 8 h, by using the bioluminescent bacterial reporter construct. Currently, we are extending our studies to include samples from a larger cohort of AML patients to investigate correlation with clinical outcome. If full clinical trials demonstrate that the as- say has predictive value, it may have the potential for development as a diagnostic kit suitable for use in a routine clinical laboratory, enabling rapid determination of the degree of response before patients undergo chemotherapy.
